Literature DB >> 9130515

High IL-5 production by human drug-specific T cell clones.

W J Pichler1, M Zanni, S von Greyerz, B Schnyder, D Mauri-Hellweg, T Wendland.   

Abstract

To analyze whether and how T cells are involved in drug allergies, we analyzed the drug-induced activation of T cell subsets, T cell receptor V-beta usage and cytokine secretion of T cells from the peripheral blood of drug-allergic individuals. The specificity of the T cells was demonstrated by specific restimulation of drug specific clones. We found that drugs which do not need to be metabolized to become immunogenic (haptens like penicillin G) can stimulate CD4+ and CD8+ T cells in vitro. The T cell response to penicillin can be oligoclonal (use of a certain T cell receptor Vbeta only) or polyclonal. Only polyclonal T cell lines were cross-reactive with other beta-lactam antibiotics. Sulfamethoxazole and lidocaine are thought to gain their ability to bind to proteins by intracellular drug metabolism. They were found to stimulate CD4+ and CD8+ T cells in vitro, and some reactive T cell lines were oligoclonal. The majority of lidocaine-specific clones secreted rather high amounts of IL-5 and IL-4 after PMA/ionomycin stimulations (Th2-like), but some CD4+ and all CD8+ clones had a Th1-like phenotype (high INF-gamma and TNF-alpha). The data clearly demonstrate the existence of drug-specific alphabeta+ T cells in the circulation of drug-allergic individuals and reveal a great heterogeneity of T-cell-mediated responses. Further studies are needed to correlate the type of T cell response to the clinical picture, which can be quite heterogeneous.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9130515     DOI: 10.1159/000237539

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  7 in total

Review 1.  Allergic reactions to drugs: involvement of T cells.

Authors:  W J Pichler; N Yawalkar
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

Review 2.  Role of bioactivation in drug-induced hypersensitivity reactions.

Authors:  Joseph P Sanderson; Dean J Naisbitt; B Kevin Park
Journal:  AAPS J       Date:  2006-02-03       Impact factor: 4.009

3.  T-cell involvement in drug-induced acute generalized exanthematous pustulosis.

Authors:  M Britschgi; U C Steiner; S Schmid; J P Depta; G Senti; A Bircher; C Burkhart; N Yawalkar; W J Pichler
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

4.  Drug antigenicity, immunogenicity, and costimulatory signaling: evidence for formation of a functional antigen through immune cell metabolism.

Authors:  Ayman Elsheikh; Sidonie N Lavergne; J Luis Castrejon; John Farrell; Haiyi Wang; Jean Sathish; Werner J Pichler; B Kevin Park; Dean J Naisbitt
Journal:  J Immunol       Date:  2010-10-27       Impact factor: 5.422

5.  Benzofuran sulfonates and small self-lipid antigens activate type II NKT cells via CD1d.

Authors:  Catarina F Almeida; Dylan G M Smith; Tan-Yun Cheng; Chris M Harpur; Elena Batleska; Catriona V Nguyen-Robertson; Tram Nguyen; Tamara Thelemann; Scott J J Reddiex; Shihan Li; Sidonia B G Eckle; Ildiko Van Rhijn; Jamie Rossjohn; Adam P Uldrich; D Branch Moody; Spencer J Williams; Daniel G Pellicci; Dale I Godfrey
Journal:  Proc Natl Acad Sci U S A       Date:  2021-08-24       Impact factor: 11.205

6.  CD1d-restricted T cell activation by nonlipidic small molecules.

Authors:  Ildiko Van Rhijn; David C Young; Jin Seon Im; Steven B Levery; Petr A Illarionov; Gurdyal S Besra; Steven A Porcelli; Jenny Gumperz; Tan-Yun Cheng; D Branch Moody
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-01       Impact factor: 11.205

7.  Mass spectrometric characterization of circulating and functional antigens derived from piperacillin in patients with cystic fibrosis.

Authors:  Paul Whitaker; Xiaoli Meng; Sidonie N Lavergne; Sabah El-Ghaiesh; Manal Monshi; Caroline Earnshaw; Daniel Peckham; Jimmy Gooi; Steve Conway; Munir Pirmohamed; Rosalind E Jenkins; Dean J Naisbitt; B Kevin Park
Journal:  J Immunol       Date:  2011-05-23       Impact factor: 5.422

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.